Public/Private Partnership Is Best Vehicle For Active Rx Surveillance System

An active drug safety surveillance system is "doable," and would cost in the tens of millions of dollars, GlaxoSmithKline Chief Medical Officer Ronald Krall said during a recent Institute of Medicine symposium on the future of drug safety